Se-lim Kim
Jeonju, 561712, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
[Corrigendum] Lipocalin 2 inversely regulates TRAIL sensitivity through p38 MAPK‑mediated DR5 regulation in colorectal cancer.
Journal: International journal of oncology
Published: July 03, 2018
Lipocalin 2 inversely regulates TRAIL sensitivity through p38 MAPK-mediated DR5 regulation in colorectal cancer.
Journal: International journal of oncology
Published: July 03, 2018
Lipocalin 2 negatively regulates cell proliferation and epithelial to mesenchymal transition through changing metabolic gene expression in colorectal cancer.
Journal: Cancer science
Published: May 19, 2017
Combined Parthenolide and Balsalazide Have Enhanced Antitumor Efficacy Through Blockade of NF-κB Activation.
Journal: Molecular cancer research : MCR
Published: March 22, 2016
Parthenolide enhances sensitivity of colorectal cancer cells to TRAIL by inducing death receptor 5 and promotes TRAIL-induced apoptosis.
Journal: International journal of oncology
Published: October 01, 2014
Balsalazide Potentiates Parthenolide-Mediated Inhibition of Nuclear Factor-κB Signaling in HCT116 Human Colorectal Cancer Cells.
Journal: Intestinal research
Published: September 01, 2014
Parthenolide exerts inhibitory effects on angiogenesis through the downregulation of VEGF/VEGFRs in colorectal cancer.
Journal: International journal of molecular medicine
Published: November 01, 2013
Parthenolide Sensitizes Human Colorectal Cancer Cells to Tumor Necrosis Factor-related Apoptosis-inducing Ligand through Mitochondrial and Caspase Dependent Pathway.
Journal: Intestinal research
Published: October 04, 2013
Parthenolide suppresses tumor growth in a xenograft model of colorectal cancer cells by inducing mitochondrial dysfunction and apoptosis.
Journal: International journal of oncology
Published: May 14, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026